Uitdehaag et al. (2015) Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs, PLoS ONE, 10 (5):e0125021.
Chou T. (2006) Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacological Reviews, 58 (3):621-681.
Zhao et al. (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses, Clinical Cancer Research, 10 (23):7994-8004.
Chou, T. (2010) Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method, Cancer Research, 70 (2):440-446.
Haagensen et al. (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition, British Journal of Cancer, 106:1386-1394.
Canté-Barrett et al. (2016) MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia, Leukemia, 30:1832-1843.
Uitdehaag et al. (2019) Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017, Molecular Cancer Therapeutics, 18 (2):470-481.
Seashore-Ludlow et al. (2015) Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset, Cancer Discovery 5:1210-1223.
Lee et al. (2018) Harnessing synthetic lethality to predict the response to cancer treatment, Nature Communications, 9:2546.